Objective:To construct an assessment system for patents'values of medically technical achievements,and explore and analyze assessment method for patents'values,so as to provide support for transferring patents of the achievements of science and research of medical technique.Methods:Aimed at the problem that quantitative assessment of patents'value existed difficulty in transferring achievements of science and research at the field of medicine-engineer integration,a comprehensively assessment model of combining analytic hierarchy process(AHP)and the entropy weight method was adopted to construct assessment indicator system for patent's value from technical value,law value,market value and policy value,which can explore the contribution and application strategy of each indicator in evaluating the transfer of the achievement of medicine-engineer integration.The data of Patyee patent databases and China national intellectual property administration were retrieved during January 2015 and June 2025.The achievement's transfers of patents of Shanghai Ninth People's Hospital,Shanghai Jiaotong University in the database during January 2024 and June 2025 were used to conduct verification for the application of assessing patents'value.Results:The assessment system for patents'values included four first-level indicators(the technical value,law value,market value and policy value of patents)and 15 second-level indicators.During 2015 and 2021,the number of applying patents of the national public hospitals increased year by year,and it slightly decreased after reached to 79 608 patents in 2021.The number of invention patents maintained a trend of continuous growth in the last decade,and the ratio of invention patents to the total number of whole applied patents reached to 53.66%in 2024,which was the first time that the number of invention patents exceeded half of the number of the total of number of the patents.There was better consistency between AHP-entropy weight method and the amount of actually achievement transfer of patents in comprehensive assessing the top 12 patents with high value at ranking for patents'value degree of Shanghai Ninth People's Hospital,Shanghai Jiaotong University.Conclusion:The evaluation result of the assessment system for patents'value of medically technical achievement for the degree of patents'value is basically consistency with the actual transfer value of patents,and the degree of patents'value of database,which can effectively evaluate the value degree of the patents of medically technical achievement,and provide basis for decision-making of transferring patents in this technical field.

Objective:To develop and validate a machine learning (ML) noninvasive model based on routine laboratory parameters to preoperatively predict the microvascular invasion (MVI) in patients with hepatocellular carcinoma (HCC).Methods:A total of 629 HCC patients who underwent hepatectomy at the First Affiliated Hospital of Fujian Medical University between January 2019 and December 2023 were retrospectively enrolled in this study and were divided chronologically into a training set ( n=464) and internal validation set ( n=165). A cohort with 190 HCC patients from Fujian Provincial Hospital were used as an external validation set. Preoperatively demographic features, tumor size and routine laboratory data were collected. All patients were divided into MVI-positive or MVI-negative group. The Boruta algorithm and LASSO regression algorithm were used to screen out related features in the training set. Eight different ML algorithms including multivariate logistic regression, decision tree (DT), random forest (RF), extreme gradient boosting (XGboost), k-nearest neighbor (KNN), support vector machine (SVM), light gradient boosting machine (LGBM) and Naive Bayes were used to construct the prediction models. The predictive performances of these models on training and internal validation sets were evaluated by the receiver operating characteristic (ROC) curve with the area under the curve (AUC). The ML model with the highest AUC values was defined as the optimal model and its performance was further validated in the external validation set. The calibration curve showed that the probability value curve was close to the actual occurrence probability curve, and the DCA showed that it could be applied within the threshold probability range of 0.3-0.8 to obtain net benefits. Results:After screening, eight parameters including α-fetoprotein (AFP), protein induced by vitamin K absence Ⅱ (PIVKA-Ⅱ), tumor size, eosinophil count, neutrophil count, creatinine, ApoA1 and total bilirubin were finally selected for the construction of the preoperative prediction model for MVI in HCC. Among all the tested eight ML algorithms, XGboost obtained the optimal performance with an AUC of 0.820 in training set, an AUC of 0.803 in internal testing set and an AUC of 0.758 in external testing set. Further stratified analysis showed that the AUC for preoperatively predicting MVI by XGboost was 0.817 for HCC patients with positive hepatitis B surface antigen, 0.779 for male patients and 0.790 for elder patients. The calibration curves showed good agreement between observed and predicted values and the decision curve analysis curve showed relatively higher net benefits.Conclusions:We successfully established and verified a novel XGboost model based on eight routine laboratory parameters with relatively high and reliable predictive accuracy to preoperatively predict MVI in HCC.

Objective:To construct an assessment system for patents'values of medically technical achievements,and explore and analyze assessment method for patents'values,so as to provide support for transferring patents of the achievements of science and research of medical technique.Methods:Aimed at the problem that quantitative assessment of patents'value existed difficulty in transferring achievements of science and research at the field of medicine-engineer integration,a comprehensively assessment model of combining analytic hierarchy process(AHP)and the entropy weight method was adopted to construct assessment indicator system for patent's value from technical value,law value,market value and policy value,which can explore the contribution and application strategy of each indicator in evaluating the transfer of the achievement of medicine-engineer integration.The data of Patyee patent databases and China national intellectual property administration were retrieved during January 2015 and June 2025.The achievement's transfers of patents of Shanghai Ninth People's Hospital,Shanghai Jiaotong University in the database during January 2024 and June 2025 were used to conduct verification for the application of assessing patents'value.Results:The assessment system for patents'values included four first-level indicators(the technical value,law value,market value and policy value of patents)and 15 second-level indicators.During 2015 and 2021,the number of applying patents of the national public hospitals increased year by year,and it slightly decreased after reached to 79 608 patents in 2021.The number of invention patents maintained a trend of continuous growth in the last decade,and the ratio of invention patents to the total number of whole applied patents reached to 53.66%in 2024,which was the first time that the number of invention patents exceeded half of the number of the total of number of the patents.There was better consistency between AHP-entropy weight method and the amount of actually achievement transfer of patents in comprehensive assessing the top 12 patents with high value at ranking for patents'value degree of Shanghai Ninth People's Hospital,Shanghai Jiaotong University.Conclusion:The evaluation result of the assessment system for patents'value of medically technical achievement for the degree of patents'value is basically consistency with the actual transfer value of patents,and the degree of patents'value of database,which can effectively evaluate the value degree of the patents of medically technical achievement,and provide basis for decision-making of transferring patents in this technical field.

Objective:To develop and validate a machine learning (ML) noninvasive model based on routine laboratory parameters to preoperatively predict the microvascular invasion (MVI) in patients with hepatocellular carcinoma (HCC).Methods:A total of 629 HCC patients who underwent hepatectomy at the First Affiliated Hospital of Fujian Medical University between January 2019 and December 2023 were retrospectively enrolled in this study and were divided chronologically into a training set ( n=464) and internal validation set ( n=165). A cohort with 190 HCC patients from Fujian Provincial Hospital were used as an external validation set. Preoperatively demographic features, tumor size and routine laboratory data were collected. All patients were divided into MVI-positive or MVI-negative group. The Boruta algorithm and LASSO regression algorithm were used to screen out related features in the training set. Eight different ML algorithms including multivariate logistic regression, decision tree (DT), random forest (RF), extreme gradient boosting (XGboost), k-nearest neighbor (KNN), support vector machine (SVM), light gradient boosting machine (LGBM) and Naive Bayes were used to construct the prediction models. The predictive performances of these models on training and internal validation sets were evaluated by the receiver operating characteristic (ROC) curve with the area under the curve (AUC). The ML model with the highest AUC values was defined as the optimal model and its performance was further validated in the external validation set. The calibration curve showed that the probability value curve was close to the actual occurrence probability curve, and the DCA showed that it could be applied within the threshold probability range of 0.3-0.8 to obtain net benefits. Results:After screening, eight parameters including α-fetoprotein (AFP), protein induced by vitamin K absence Ⅱ (PIVKA-Ⅱ), tumor size, eosinophil count, neutrophil count, creatinine, ApoA1 and total bilirubin were finally selected for the construction of the preoperative prediction model for MVI in HCC. Among all the tested eight ML algorithms, XGboost obtained the optimal performance with an AUC of 0.820 in training set, an AUC of 0.803 in internal testing set and an AUC of 0.758 in external testing set. Further stratified analysis showed that the AUC for preoperatively predicting MVI by XGboost was 0.817 for HCC patients with positive hepatitis B surface antigen, 0.779 for male patients and 0.790 for elder patients. The calibration curves showed good agreement between observed and predicted values and the decision curve analysis curve showed relatively higher net benefits.Conclusions:We successfully established and verified a novel XGboost model based on eight routine laboratory parameters with relatively high and reliable predictive accuracy to preoperatively predict MVI in HCC.

OBJECTIVE To explore the intestinal absorption characteristics of saikosaponins. METHODS Based on everted intestinal sac model， using accumulative absorption amount （Q） and absorption rate constant （Ka） as indexes， UHPLC-MS/MS technique as a method， the absorption of saikosaponin A， B2， C， D and F from total saponins of Bupleurum chinense （8 g/mL， by crude drug） in the duodenum， jejunum and ileum was detected. RESULTS The correlation coefficients （r） of the regression equations for the absorption of saikosaponins A， B2， C and F in the duodenum， jejunum and ileum were all higher than 0.95， while the r of saikosaponin D in the above intestinal segments was lower than 0.95； compared with the absorption of the same composition in the duodenum， the Q and Ka of saikosaponin A and C circulating in jejunum and ileum for 120 min， as well as the Q and Ka of saikosaponin F circulating in the ileum for 120 min were significantly decreased （P＜0.05）. CONCLUSIONS Saikosaponin A and the other 4 saikosaponins are all absorbed in the duodenum， jejunum and ileum； among them， saikosaponin A， B2， C and F are linearly absorbed， which conforms to the zero-order absorption characteristics， but saikosaponin D shows non- linear absorption.

The majority of incidentally found and screen-detected lung cancer is manifested as ground-glass nodule (GGN), which is more likely to be detected in the young people, women and non-smokers. An appropriate management strategy for GGN can not only reduce the mortality of lung cancer but also minimize overtreatment. Although most of persistent GGNs are finally diagnosed as adenocarcinoma or precursor glandular lesions, the GGN-featured lung cancer is characterized as indolent growth or even non-growth. Therefore, scheduled follow-up might be safe for the special radiologic type under a certain condition. We should design the individualized diagnosis and treatment strategy for each patient. The treatment decision-making depends on various factors, including invasion, dynamic change, efficacy and safety of the treatment, as well as physical and psychic condition of the patients. Different from other types of lung cancer, the indolent feature of GGN-featured lung cancer allows a long time to intervene. Therefore, the determination of proper timing for intervention should be made cautiously. Surgical resection is still the principal treatment for GGN-featured lung cancer. However, there is still no consensus on the optimal surgical approach for GGN-featured lung adenocarcinoma. Currently, sublobar resection without lymphadenectomy has been recommended to the patients with precursor glandular lesions. In light of the GGN-featured lung cancer which generally represents a local lesion, local ablation therapies have been used in those patients, especially in the ones who are inoperable or refuse to undergo surgery. The percutaneous local ablation includes different techniques: radiofrequency ablation, microwave ablation and argon-helium cryoablation. The local ablation is safe, minimally invasive and repeatable. In addition, it offers the advantage to biopsy and treatment synchronously. Percutaneous ablation has the potential to be an alternative of surgery to cure GGN-featured lung cancer based on emerging evidences. The efficacy of transbronchial ablation guided by  ultrasound or electromagnetic navigational system in the treatment of GGN-featured lung cancer has been primarily validated. As a developing technology, it might be a promising approach but needs further exploration. With the advance in ablation technology, we do believe that the interventional therapy will play an equal role as surgery in curative treatment of GGN-featured lung cancer in the future. Personalized treatment considering the condition of patients and the features of the lesion will maximize the benefit of every patient. This article will explore the diagnosis and treatment strategies of GGN on the basis of further understanding of GGN, and introduce the application of ablation therapy in GGN from the perspective of respiratory intervention.

Objective To investigate the clinical manifestation,neuroimaging characteristics and follow-up results of chorea associated with non-ketotic hyperglycemia (C-H-BG).Methods Clinical data of six patients with C-H-BG were analyzed retrospectively.Results The average age of the six patients (five female and one male) was 65.8±13.9 years,All patients had acute-subacute course.Patients presented with choreic movements involving facial muscles (n=6) and unilateral (n=5) or bilateral limbs (n=1).The average value of plasma glucose at admission was 9.21 ± 5.15 mmol/L.All patients had significantly elevated HbA1c (14.1 ±3.5％).The brain MRI T1 imaging from all patients showed hyperintensity in the basal ganglia,putamen,lenticular nucleus and caudate nucleus.SWI imaging revealed corresponding hypointensity signal in the basal ganglia in three patients.Two patients had severe stenosis of the MCA.Five patients were followed up for an average of 16.2 ±7.2 months.Three patients died.Conclusion The high T1 hypertense lesions in the basal ganglia are the mainly radiological feature of C-H-BG which may be accompanied by SWI hytointense signals in the basal ganglia.

Objective To explore the efficacy and adverse reaction of nedaplatin (NDP)+gemcitabine (GEM)and cisplatin (DDP)+GEM for advanced lung squamous cell carcinoma.Methods A total of 1 01 cases advanced untreated patients from September 201 2 to December 201 3 were randomly divided into 2 groups using random number table method:69 patients in the observation group accepted NDP+GEM treatment and 32 patients in the control group received DDP +GEMtreatment.The objective response rate (RR),disease control rate (DCR ) and progression-free survival (PFS ) and adverse reaction were collected and evaluated. Results RR was 28.6%(1 8/63)in the observation group and 1 5.6%(5/32)in the control group,DCR was 81 .0%(51/63)in the observation group and 68.8%(22/32)in the control group (χ2 =1 .36,P=0.24;χ2 =1 .67,P=0.20).The median PFS was 4.52 months and 4.01 months in the observation group and control group (χ2 =0.09,P=0.73).The major adverse reaction was myelosuppression in both groups (33.3% vs.37.5%,χ2 =0.1 7,P=0.68).The incidence ofⅢ-Ⅳ grade nausea and vomiting was lower in the observation group, compared with the control group (1 4.5%vs.56.3%,χ2 =1 9.02,P=0.05).Conclusion NDP combined with GEM in advanced lung squamous cell carcinoma of the first-line treatment has equivalent efficacy to DDP+GEM, with lower incidence of adverse reaction,which is worthy of further dissemination of research.

Objective To investigate the dosimetric performance of COMPASS system,a novel 3D quality assurance system for the verification of nasopharyngeal carcinoma volumetric modulated therapy (VMAT) treatment plan.Methods Eight VMAT treatment plans of nasopharyngeal carcinoma patients were performed with MasterPlan,a treatment planning system (TPS),and then these treatment plans were sent to the COMPASS and MOSAIQ system,a coherent control system,respectively.Comparison of the COMPASS reconstructed dose versus TPS dose was conducted by using the dose volume-based indices:dose received by 95％ volume of target ( D95％ ),mean dose ( Dmean ) and γ pass rate,dose to the 1％ of the spinal cord and brain stem volume ( D1％ ),mean dose of leaf and right parotid ( Dmean ),and the volume received 30 Gy for left and right parotid (V30).COMPASS can reconstruct dose with the real measured delivery fluence after detector commissioning.Results The average dose difference for the target volumes was within 1％,the difference for D95 was within 3％ for most treatment plans,and the γ pass rate was higher than 95％ for all target volumes.The average differences for the D1％ values of spinal cord and brain stem were ( 4.3 ± 3.0) ％ and ( 5.9± 2.9 ) ％ respectively,and the average differences for the Dmean values of spinal cord and brain stem were ( 5.3 ± 3.0 ) ％ and ( 8.0 ± 3.5 ) ％ respectively.In general the COMPASS measured doses were all smaller than the TPS calculated doses for these two organs.The average differences of the Dmean values of the left and right parotids were( 6.1± 3.1 ) ％ and ( 4.7 ± 4.4 ) ％ respectively,and the average differences of the V30 values of the left and right parotids were (9.4 ± 7.5 ) ％ and (9.4 ± 9.9)％ respectively.Conclusions An ideal tool for the VMAT verification,the patient anatomy based COMPASS 3D dose verification system can check the dose difference between the real delivery and TPS calculation directly for each individual organ,either target volumes or critical organs.

ObjectiveTo evaluate the efficacy, feasibility and safety of CT guided percutaneous 125Ⅰ seeds implantation in elderly patients of stage Ⅰperipheral non-small cell lung cancer ( NSCLC ).MethodsClinical data of 16 elderly peripheral stage Ⅰ NSCLC patients ( 10 squamous carcinoma and 6adenocarcinoma;13 stage ⅠA and 3 stage ⅠB ) who received radioactive 125Ⅰ seeds implantation because of refusal or being unsuited to operation or external radiotherapy were retrospectively analyzed. Prescribed dose was 140 - 160 Gy. Under CT guidance, 125Ⅰ seeds were implanted percutaneously into tumors for interstitial radiotherapy according to treatment plan system. ResultsMean number of 125Ⅰ seeds each patient received was21.1. 12 complete response (CR) and 4 partial response (PR) were achieved. Total response rate ( CR + PR) was 100％. 100％ patients completed 10 to 56 months of follow-up, 15, 13, 8 and 6 patients completed 1-, 2-, 3-and 4-years'follow-up, respectively. The median local progression free time was 14months. The 1-,2-,3-and 4-year overall survival rate were 60％, 54％, 50％ and 33％, respectively (median:14 months). 7 cases died of non-tumor disease and 5 died of metastasis. No severe complications were observed. ConclusionsCT guided 125Ⅰ seeds implantation is a safe, reliable and effective radical treatment method for elderly stage Ⅰ peripheral NSCLC patients, who refuse to or are unsuitable to operation or external radiotherapy.